Bizengri (Zenocutuzumab-Zbco) for Lung Cancer

Overview
Bizengri is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval for the treatment of adults with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion. This approval is contingent on results from confirmatory trials, as it is based on overall response rate and duration of response. Bizengri is also known by its drug name, zenocutuzumab-zbco.

Bizengri is a bispecific antibody targeting HER2 and HER3, proteins involved in cancer growth. It works by interfering with signaling pathways that promote tumor cell proliferation in cancers with NRG1 gene fusions. This mechanism may help slow disease progression.

How do I take it?
Prescribing information states that Bizengri is administered as an intravenous infusion. Typically, a person will  receive the drug every two weeks until disease progression or unacceptable toxicity occurs. Before each infusion, premedications are generally given to reduce the risk of infusion-related reactions. The treatment should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Bizengri include diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea (difficulty breathing), rash, constipation, vomiting, abdominal pain, and edema (swelling). Common Grade 3 or 4 laboratory abnormalities include changes in liver enzymes (such as increased AST, ALT, and alkaline phosphatase), decreased hemoglobin, sodium, platelets, magnesium, and phosphate, and increased bilirubin and aPTT (a measure of blood clotting).

Rare but serious side effects may include infusion-related reactions (which can include life-threatening anaphylaxis), interstitial lung disease (inflammation or scarring of the lungs), left ventricular dysfunction (reduced heart function that can lead to heart failure), and embryo-fetal toxicity (harm an unborn baby).

For more information about this treatment, visit:

Bizengri (Zenocutuzumab-Zbco) Injection, for Intravenous Use — Merus

Bizengri — Drugs.com